Synthetic Poly(L-Glutamic Acid)-conjugated CpG Exhibits Antitumor Efficacy With Increased Retention in Tumor and Draining Lymph Nodes After Intratumoral Injection in a Mouse Model of Melanoma.
There is an urgent need for new clinically applicable drug-delivery methods to enhance accumulation of immune-activating drugs in tumors. We synthesized a poly(L-glutamic acid)-CpG ODN2216 conjugate (PG-CpG) and injected it intratumorally into C57BL/6 mice bearing subcutaneous B16-ovalbumin melanoma. PG-CpG elicited the same potent antitumoral activity as CpG with respect to reducing tumor growth and triggering antigen-specific CD8 T-cell responses in this well-established solid tumor model. Moreover, PG-CpG was retained significantly longer in both tumor and draining lymph nodes than was free CpG after intratumoral injection. Specifically, 48 hours after injection, 26.5%±16.9% of the injected PG-CpG dose versus 4.72%±2.61% of free CpG remained at the tumor, and 1.53%±1.22% of the injected PG-CpG versus 0.37%±0.33% of free CpG was retained in the draining inguinal lymph nodes. These findings indicate that PG is an effective synthetic polymeric carrier for delivery of immunostimulatory agents to tumors and lymph nodes.
Departments of *Stem Cell Transplantation and Cellular Therapy †Shanghai Pulmonary Hospital, Tongji University School of Medicine, Shanghai, China ‡Melanoma Medical Oncology §Cancer Systems Imaging ∥Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, TX.
Qing
Q
Ma
Dapeng
D
Zhou
Elizabeth S
ES
DeLyria
Xiaoxia
X
Wen
Wei
W
Lu
Prakash
P
Thapa
Chengwen
C
Liu
Dan
D
Li
Roland L
RL
Bassett
Willem W
WW
Overwijk
Patrick
P
Hwu
Chun
C
Li
D000818:Animals; D004195:Disease Models, Animal; D016503:Drug Delivery Systems; D005260:Female; D018698:Glutamic Acid / Q000737:chemistry; D006801:Humans; D015552:Injections, Intralesional; D008198:Lymph Nodes / Q000378:metabolism*; D008546:Melanoma, Experimental / Q000378:metabolism / Q000628:therapy*; D051379:Mice; D008810:Mice, Inbred C57BL; D009838:Oligodeoxyribonucleotides / Q000737:chemistry / Q000627:therapeutic use*; D011108:Polymers / Q000737:chemistry; D012878:Skin Neoplasms / Q000378:metabolism / Q000628:therapy*; D051217:Toll-Like Receptor 9 / Q000819:agonists; D047368:Tumor Burden
C526902:CpG ODN 2216; D009838:Oligodeoxyribonucleotides; D011108:Polymers; D051217:Toll-Like Receptor 9; D018698:Glutamic Acid
Biomaterials. 2010 Sep;31(25):6567-73
20537382
Vaccine. 2001 Oct 12;20(1-2):148-57
11567759
J Immunother. 2011 Apr;34(3):279-88
21389870
Bioconjug Chem. 2007 Jan-Feb;18(1):77-83
17226959
Cancer Immunol Immunother. 2001 Dec;50(10 ):503-14
11776372
Nat Biotechnol. 2004 Jan;22(1):93-7
14661026
Nature. 2014 Mar 27;507(7493):519-22
24531764
Cancer Chemother Pharmacol. 2007 Mar;59(4):537-48
16924498
Expert Opin Biol Ther. 2005 May;5(5):673-82
15934842
Nat Rev Drug Discov. 2006 Jun;5(6):471-84
16763660
Cancer Gene Ther. 2003 Sep;10(9):661-8
12944985
PLoS One. 2013 May 15;8(5):e63550
23691064
Cancer Chemother Pharmacol. 2000;46(5):416-22
11127947
Clin Cancer Res. 2005 Nov 1;11(21):7834-40
16278406
J Immunol. 2008 Sep 1;181(5):2990-8
18713969
Cancer Immunol Immunother. 2004 Apr;53(4):338-44
14618278
Invest Radiol. 2007 Aug;42(8):569-78
17620940
Cancer Immunol Immunother. 2007 Aug;56(8):1251-64
17242927
Cancer Res. 1998 Jun 1;58(11):2404-9
9622081
Eur J Immunol. 2007 Feb;37(2):306-9
17273997
Pharm Res. 2007 Jun;24(6):1217-24
17377742
J Immunother. 2006 Sep-Oct;29(5):558-68
16971811
Bioconjug Chem. 2004 Nov-Dec;15(6):1408-15
15546209
Nat Med. 2004 Feb;10(2):187-92
14745443
J Pharm Sci. 2001 Feb;90(2):182-93
11169535
Clin Cancer Res. 2012 Oct 15;18(20):5628-38
22904105
Adv Drug Deliv Rev. 2008 May 22;60(8):886-98
18374448
Clin Cancer Res. 1999 Apr;5(4):891-7
10213226
J Immunother. 2004 Nov-Dec;27(6):460-71
15534490
Adv Drug Deliv Rev. 1999 Apr 5;37(1-3):295-312
10837741